
SeneXta Therapeutics SA Announces Human Dosing with SNX-001 in Phase I Study

Lugano, Switzerland - December 10, 2009 - SeneXta Therapeutics SA announces the dosing of the first subject for its lead compound SNX-001 in a cGCP double-blind placebo-controlled study conducted in Germany under an FDA approved protocol.

"The initiation of our first clinical trial represents an important milestone for SeneXta. SNX-001 is a new approach to acetylcholinesterase (AChE) inhibitor therapy that can significantly improve the treatment of dementia", said Enrico Braglia, Senexta's CEO.

SNX-001 is a small molecule developed as a novel oral long-lasting AChE inhibitor to treat Alzheimer's (AD) and other cognitive impairment disorders. In preclinical studies and animal models SNX-001 has shown excellent efficacy, selectivity, brain penetration and pharmacologic activity. Previous exploratory clinical studies of SNX-001 showed potent long-lasting memory and ADAS-Cog improvement in a small cohort of AD patients.

"This phase I study represents the cornerstone for SeneXta to reach a solid clinical proof of concept with SNX-001 for the treatment of AD" said Ruggero Fariello, MD, Senexta's Chief Medical Advisor. "If we succeed in reproducing previous clinical data we will have made a significant leap forward in AD drug development"

SeneXta's randomized, double-blind, placebo-controlled Phase I trial in healthy aged volunteers is designed as a single and multiple doses escalation study to confirm the previously reported safety profile and establish the pharmacokinetic and pharmacodynamic profile of SNX-001. Twenty-four subjects will receive one of three different doses or a placebo. The Phase I clinical trial is being conducted in Germany under a BfArM and FDA approved protocol. The company expects to generate human clinical data by the second quarter of 2010 and to begin Phase II studies in Alzheimer's patients by year end.

About SNX-001

SNX-001 is a selective and novel inhibitor of acetylcholinesterase (AChE) for the treatment of Alzheimer's disease. SNX-001 produces long-acting AChE inhibition, which improves its brain selectivity and reduces the peripheral toxicity that limits the use of currently available short acting inhibitors. SNX-001 has been developed specifically to exploit higher levels of AChE inhibition in the brain that are left out of the reach of short acting inhibitors. SNX-001 not only increases AChE inhibition in the brain above what can be achieved clinically at the present time, but the side-effect profile is greatly improved, especially with regard to GI effects.

About SeneXta Therapeutics SA

SeneXta is a privately held Swiss biopharmaceutical company engaged in the research and development of therapies for neurodegenerative disorders including Alzheimer's disease, cognitive impairment secondary to ischemia, and other central nervous system (CNS) disorders. SeneXta was founded to acquire intellectual properties for the treatment of CNS disorders. The Company has already recruited a world-leading team of CNS experts and established solid collaborations with U.S. and European Union universities.

For more information:

SENEXTA THERAPEUTICS SA

Via Cantonale 1
6900 Lugano
Switzerland

info@senexta.com